Ergoloid mesylates and ECT.
Amnesia is the most common adverse effect among patients receiving electroconvulsive therapy. In a double-blind pilot study, patients receiving bilateral ECT were pretreated with ergoloid mesylates (N = 5) or placebo (N = 5). Consistent with the hypothesis that ergoloid mesylates might protect against ECT-associated amnesia, nonsignificant trends on some memory tests showed better performance for patients receiving active treatment. Unexpectedly, patients treated with ergoloid mesylates had a significantly better antidepressant response.
Sachs
G S
GS
Department of Psychiatry, Harvard Medical School, Boston, MA.
Gelenberg
A J
AJ
Bellinghausen
B
B
Wojcik
J
J
Falk
W E
WE
Farhadi
A M
AM
Jenike
M
M
D000647:Amnesia / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy / Q000009:adverse effects; D006801:Humans; D008568:Memory / Q000187:drug effects; D010555:Personality Inventory; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales
D004088:Dihydroergotoxine